MinorNon-ergot dopamine D2/D3 receptor agonist×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Vortioxetine is metabolised in the liver mainly by CYP2D6 and to a lesser extent by CYP3A4/5 and CYP2C9, and it does not itself inhibit or induce cytochrome P450 enzymes (Brintellix SmPC, European Medicines Agency, EMA). Pramipexole is hardly metabolised: about 90% of the dose is excreted unchanged by the kidneys. Less than 20% is bound to plasma proteins, so interactions through hepatic metabolism or protein binding are unlikely (Mirapexin SmPC, EMA). The risk of serotonin syndrome and neuroleptic malignant syndrome with vortioxetine rises with antipsychotics and other dopamine antagonists (Brintellix SmPC, EMA), whereas pramipexole is a dopamine agonist (Mirapexin SmPC, EMA). The documents do not describe vortioxetine as one of the sedative drugs that call for caution with pramipexole: it did not increase the incidence of somnolence compared with placebo (Brintellix SmPC, EMA).
Symptoms
The documents describe no symptoms linked to this combination. The most common adverse reaction to vortioxetine is nausea, and dizziness also occurs (Brintellix SmPC, European Medicines Agency, EMA). Pramipexole causes nausea, dizziness, somnolence up to sudden sleep onset during the day, orthostatic hypotension, hallucinations and impulse control disorders such as pathological gambling or compulsive shopping (Mirapexin SmPC, EMA).
Management
According to the documents, the combination is acceptable, and the doses of vortioxetine and pramipexole need no change. No document names the pair (Brintellix and Mirapexin SmPCs, European Medicines Agency, EMA). Pramipexole is combined with sedative drugs and alcohol with caution. If somnolence or episodes of sudden sleep onset occur, the patient should not drive, and a dose reduction or stopping pramipexole is considered (Mirapexin SmPC, EMA). Vortioxetine can also cause dizziness, so caution is needed when driving at the start of treatment and after a dose change (Brintellix SmPC, EMA). Because of the risk of orthostatic hypotension, blood pressure is monitored, especially when pramipexole is started (Mirapexin SmPC, EMA). In Parkinson's disease, pramipexole is not stopped abruptly: the dose is tapered because of the risk of neuroleptic malignant syndrome and dopamine agonist withdrawal syndrome (Mirapexin SmPC, EMA). Impulse control disorders and mania are monitored regularly during pramipexole treatment (Mirapexin SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: TRINTELLIX (vortioxetine) tablets prescribing information (Takeda) (2025)– FDA, DailyMed setid 1a5b68e2-14d0-419d-9ec6-1ca97145e838 (Takeda Pharmaceuticals America), revisión 02/2025 (versión 18, vigente desde 05.03.2025), secciones 2.4, 4, 5.2 y 7.1
- EMA: Ficha técnica: Pramipexol – Mirapexin (EU/1/97/051), sección 4.5 (2026)– EMA, SmPC Mirapexin 0,18 mg comprimidos (Boehringer Ingelheim International, EU/1/97/051), texto en CIMA nº 97051003, consultado 03.11.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 4.7 y 5.2
- FDA: Pramipexole dihydrochloride tablets (Torrent) prescribing information (2026)– FDA, DailyMed setid 60167d7c-469f-455a-a113-561841af5e59 (Torrent Pharmaceuticals; the Mirapex brand label is not current in DailyMed), revised 03/2026 (version 22), sections 4, 5.1, 5.2, 7.1 and 12.3